Clinical trials: Prostate Cancer With Intermediate Risk
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen…
- Trial name
- NCT04727736
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ashok Muthukrishnan
Prostate Cancer (Adenocarcinoma), Erectile Abnormalities
PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
- Conditions
- Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male
- Trial name
- PRIAPUS-PCa (NCT07460726)
- Testing
- SBRT combined with ADT
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- CancerCare Manitoba
Prostate Cancer
SRT Versus SRT+ADT in Prostate Cancer
To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate Stereotactic radiotherapy (SRT).
- Trial name
- SPA (NCT05019846)
- Testing
- Triptorelin Embonate, Bicalutamide 50 mg
- Where
- Italy
- Volunteers
- 310 people
- Sponsor
- Marco Lorenzo Bonu
Prostate Cancer
Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy
Prostate cancer is currently the second most common cause of cancer death in men in Western countries. Lymphadenectomy is the gold standard procedure for staging pelvic lymph node and is classically indicated in intermediate and…
- Trial name
- LFD (NCT01812902)
- Testing
- Radical Prostatectomy
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- University of Sao Paulo
Prostate Cancer
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation…
- Trial name
- NCT00003104
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
The study is to examine a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer.
- Trial name
- NCT02874014
- Testing
- Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as…
- Trial name
- VANDAAM (NCT02723734)
- Testing
- Decipher® Testing
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care.
- Trial name
- NCT01342367
- Testing
- Bicalutamide, Dutasteride, Finasteride
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Chicago
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from…
- Trial name
- ReCAP (NCT00583492)
- Testing
- Ad5-yCD/mutTKSR39rep-ADP, IMRT
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Henry Ford Health System
Adenocarcinoma of the Prostate
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with…
- Trial name
- CCRO025 (NCT02064036)
- Testing
- Stereotactic Radiosurgical Boost, Casodex, Leuprolide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Davis
Prostate Cancer
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
This phase II trial studies the effect of rectal spacer hydrogel before radiation therapy in reducing radiation dose to the rectum in patients with prostate cancer.
- Trial name
- NCT05224869
- Testing
- Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer, Neoadjuvant Therapy
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy…
- Conditions
- Prostate Cancer, Neoadjuvant Therapy, Androgen Antagonists, Prostatectomy
- Trial name
- ARNEO (NCT03080116)
- Testing
- ARN-509, Degarelix
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer
High dose radiotherapy is a very effective treatment for prostate cancer. However, there is an increased risk of side effects compared to lower dose radiotherapy. This study will investigate the use of dose painting radiotherapy.
- Trial name
- BIOPROP20 (NCT02125175)
- Testing
- Hypofractionated IMRT boost Radiotherapy
- Where
- United Kingdom
- Volunteers
- 55 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Prostate Cancer
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients…
- Trial name
- NCT03290508
- Testing
- Prolaris Testing
- Where
- 34 sites in United States
- Volunteers
- 524 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease
Multi-modality therapy that includes a brachytherapy implant improves outcomes in locally advanced prostate cancer when compared to other radiation-based treatments, but is also associated with more adverse side effects.
- Trial name
- OPTiMAL (NCT03836196)
- Testing
- LDR Brachytherapy and External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
This is a research study to test an investigational drug (Not FDA approved), Apalutamide given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk prostate cancer who have already selected to…
- Trial name
- NCT02770391
- Testing
- Leuprolide acetate, Apalutamide, Radical prostatectomy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center